LOS ANGELES, CA / ACCESSWIRE / March 2, 2017 / CBDual Biotechnology Corp. (“CBDUAL”) announced today the completion of the company’s new clinical trial center in Southern California.
CBDual’s new facility provides patients with easy access to participate in clinical trials of new medical cannabis medications, therapies, and products. CBDual will develop protocols to improve patient safety and data integrity in clinical research trials in compliance with the HIPAA.
The first scheduled trial will study the medicinal and therapeutic effects of CBD on oral health. The study anticipates between 1,000-2,000 patients and will test the effects of different CBD based mouthwashes and toothpastes.
CBDual has recently entered into a cross licensing agreement with Cavitation Technologies, Inc (OTCQB: CVAT; Berlin: WTC). This agreement covers intellectual property involving the application of technology and patented processes to produce high quality pharmaceutical grade cannabis materials with increased bio-availability and increased shelf life.
Dr. Greg Rubin, CEO of CBDual Biotechnology Corp., previously commented, “The improvement of consumer and medical products require the development of the best quality and utilization of the most innovative technologies in order to achieve ultimate results. The impact of the new clinical research brings us one step closer to introducing our new products to the US markets.”
Recent breakthroughs in Cannabinoid (CBD) therapies and orally administered products prompt strong forecast for 2017. The Hemp Business Journal estimated that the CBD market will emerge as a $2.1 billion market in consumer sales by 2020. That represents a 700% increase from 2016. According to the National Institute on Drug Abuse, a number of studies have shown that CBD is a non-psychoactive cannabinoid and has a wide range of medical benefits, such as anti- inflammatory and anti-oxidant and many other health related benefits.
About CBDual Biotechnology Corp
CBDual Biotechnology is a privately held; US based Biotechnology Company with a proprietary technology for enhanced oral delivery of bioactive cannabinoids. This technology promotes good gums health and overall dental health due to higher effectiveness of the delivery methodology. Company was founded in 2016 and is headquartered in California with its R&D capability in Israel and Ukraine..
About Cavitation Technologies, Inc.
Founded in 2007, the company designs and manufactures state-of-the-art, flow-through, devices and systems as well as develops processing technologies for use in edible oil refining, renewable fuel production, expeditious petroleum upgrading, algae oil extraction, alcoholic beverage enhancement, water treatment and cannabidiol processing. As an add-on to its existing neutralization systems, the company’s patented Nano Reactor™ allows refiners to significantly reduce both processing costs and environmental impact, while also increasing yield.
Forward Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding the anticipated installation and the timing of the installation, our intent to continue to focus on research and development, marketing and sales of our unique technology, our belief that our company is positioned for accelerated growth and the expected efforts to be made to enhance our shareholder’s value. These forward-looking statements are based largely on the Company’s expectations and are subject to a number of risks and uncertainties, certain of which are beyond the Company’s control. Actual results could differ materially from these forward looking statements as a result of a variety of factors including, among others, the state of the economy, the competitive environment and our ability to perform the installation as anticipated and other factors described in our most recent Form 10-K and our other filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. In light of these risks and uncertainties there can be no assurances that the forward looking statements contained in this press release will in fact transpire or prove to be accurate. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Cavitation Technologies, Inc.
Phone (818) 718-0905
SOURCE: CBDual Biotechnology Corp.